Skip to main content

Table 6 Cox proportional hazards regression analysis for distant metastases–free survival in the T1/T2 N0 subgroup

From: The prognostic significance of pretreatment squamous cell carcinoma antigen levels in cervical cancer patients treated by concurrent chemoradiation therapy and a comparison of dosimetric outcomes and clinical toxicities between tomotherapy and volumetric modulated arc therapy

Variable

HR

95% CI

P value

Age ≥ 60 years

5.94

0.49–71.71

0.161

OTT of RT > 61 days

1.48

0.11–19.78

0.767

Pretreatment SCC Ag > 10 ng/mL

12.40

0.85–181.40

0.066

Post-treatment SCC Ag > 1.5 ng/mL

0.001

0.00–1.078E33

0.863

EQD2 of Point A ≥ 81 Gy

1.15

0.077–16.98

0.921

RT techniquea

  

0.991

VMAT

227.32

0.00–2.350E178

0.979

Tomotherapy

192.6

0.00–1.995E178

0.980

  1. HR hazard ratio, CI confidence interval, OTT overall treatment time, RT radiation therapy, SCC Ag squamous cell carcinoma antigen, EQD2 equivalent dose in 2-Gy fractions, VMAT volumetric modulated arc therapy
  2. aReference category: 3DCRT, three-dimensional conformal radiation therapy